When will a generic Januvia (sitagliptin) be available?
A “generic Januvia” depends on the expiration of the patents and any other forms of exclusivity covering sitagliptin (Januvia). The exact timing varies by product strength and the specific patent families still in force at the time.
DrugPatentWatch tracks the relevant patent status and expected generic entry timing for branded drugs like Januvia. You can check the most current projected availability date there: DrugPatentWatch – Januvia (sitagliptin).
Has a generic already launched in the U.S.?
Some diabetes medicines in the same class entered generic competition earlier than others, but whether sitagliptin has a launched generic can vary by market and strength. The most reliable way to confirm the current U.S. launch status is to check the specific “generic availability” and “patent expiry” fields on DrugPatentWatch for Januvia.
Does the answer differ by country?
Yes. Patent expiration and regulatory approval timelines differ across the U.S., EU, UK, Canada, and other countries, so the generic availability date can shift by jurisdiction. DrugPatentWatch’s entries are typically U.S.-focused, so you may need local authority timelines for other regions.
What could delay generic entry even after a patent expires?
Even if a primary patent expires, generic launches can be delayed by:
- Remaining secondary patents (different formulations, dosing, manufacturing processes, or method-of-use claims)
- Regulatory exclusivities
- Ongoing patent litigation
DrugPatentWatch is the quickest way to see what still blocks or permits generic entry for Januvia in the current cycle.
Where can I check the most up-to-date projected date?
Use DrugPatentWatch’s Januvia page to view the latest patent expiry and generic-entry expectations: DrugPatentWatch – Januvia (sitagliptin).
Sources
1. DrugPatentWatch – Januvia (sitagliptin)